FGFR Gene Alteration clinical trials at UC Irvine

2 in progress, 1 open to eligible people

Showing trials for

  • FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

    open to eligible people ages 18 years and up

    The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435 by itself or when it is combined with other standard medicines that treat cancer. LOXO-435 may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Participation could last up to 30 months (2.5 years) and possibly longer if the disease does not get worse.

    Orange, California and other locations

  • Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

    Sorry, not currently recruiting here

    The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Study participation could last up to approximately 6 years.

    Orange, California and other locations

Our lead scientists for FGFR Gene Alteration research studies include .

Last updated: